Marco Ruella MD
Assistant Professor of Medicine and Scientific Director of the Lymphoma Program
Development of next-generation chimeric antigen receptor immunotherapies for cancer
Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory cancer.
Marco Ruella
Biomedical Science